Use of Screening Algorithms and Computer Systems to Efficiently Signal Higher-Than-Expected Combinations of Drugs and Events in the US FDA??s Spontaneous Reports Database

Abstract

Since 1998, the US Food and Drug Administration (FDA) has been exploring new automated and rapid Bayesian data mining techniques. These techniques have been used to systematically screen the FDA's huge MedWatch database of voluntary reports of adverse drug events for possible events of concern. The data mining method currently being used is the Multi-Item Gamma Poisson Shrinker (MGPS) program that replaced the Gamma Poisson Shrinker (GPS) program we originally used with the legacy database. The MGPS algorithm, the technical aspects of which are summarised in this paper, computes signal scores for pairs, and for higher-order (e.g. triplet, quadruplet) combinations of drugs and events that are significantly more frequent than their pair-wise associations would predict. MGPS generates consistent, redundant, and replicable signals while minimising random patterns. Signals are generated without using external exposure data, adverse event background information, or medical information on adverse drug reactions. The MGPS interface streamlines multiple input-output processes that previously had been manually integrated. The system, however, cannot distinguish between already-known associations and new associations, so the reviewers must filter these events. In addition to detecting possible serious single-drug adverse event problems, MGPS is currently being evaluated to detect possible synergistic interactions between drugs (drug interactions) and adverse events (syndromes), and to detect differences among subgroups defined by gender and by age, such as paediatrics and geriatrics. In the current data, only 3.4% of all 1.2 million drug-event pairs ever reported (with frequencies > or = 1) generate signals [lower 95% confidence interval limit of the adjusted ratios of the observed counts over expected (O/E) counts (denoted EB05) of > or = 2]. The total frequency count that contributed to signals comprised 23% (2.4 million) of the total number, 10.4 million of drug-event pairs reported, greatly facilitating a more focused follow-up and evaluation. The algorithm provides an objective, systematic view of the data alerting reviewers to critically important, new safety signals. The study of signals detected by current methods, signals stored in the Center for Drug Evaluation and Research's Monitoring Adverse Reports Tracking System, and the signals regarding cerivastatin, a cholesterol-lowering drug voluntarily withdrawn from the market in August 2001, exemplify the potential of data mining to improve early signal detection. The operating characteristics of data mining in detecting early safety signals, exemplified by studying a drug recently well characterised by large clinical trials confirms our experience that the signals generated by data mining have high enough specificity to deserve further investigation. The application of these tools may ultimately improve usage recommendations.

Prevalence of ADRs and Associated Factors of Antiretroviral Treatment on HIV Positive Adults at Jush

“…25 ADRs may occur following a single dose or prolonged administration of medicine or result from the combination of two or more medicines. HIV-infected patients at the beginning of the antiretroviral treatment can frequently show a wide variety of adverse drug effects such as rashes, hyper pigmentation, hair loss, hypersensitivity reactions, injection site reaction, urticarial reaction, erythema multiform, toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome (SJS).…”

Quantitative signal detection for vaccines: Effects of stratification, background and masking on GlaxoSmithKline’s spontaneous reports database

“…5,14 Although we did not assess whether all scores that moved from above to below the thresholds (Quadrant D) represented false signals, their relatively low magnitude seems to suggest this. Other researchers have made similar observations using Gamma Poisson Shrinker on other adverse events database.…”

“…The EB05 is a conservative measure that is supposed to minimize false positive signals. 20 Drug-event combinations with an EB05 ≥2.0 are frequently considered signals for drug-adverse events pairs based on the empiric threshold described by Szarfman et al 14 In addition, results of a simulation study 22 provided empirical evidence that using this threshold provides a degree of conservatism in exchange for the false signal rate in the data.…”

Analysis of the Interaction between Clopidogrel, Aspirin, and Proton Pump Inhibitors Using the FDA Adverse Event Reporting System Database

“…15,16) The reporting odds ratio (ROR), 17) the proportional reporting ratio (PRR), 18) the information component (IC), 19) and the empirical Bayes geometric mean (EBGM) 20) are widely used: the PRR is currently used by the Medicines and Healthcare Products Regulatory Agency, United Kingdom: the ROR by the Pharmaceuticals and Medical Devices Agency in Japan and the Netherlands Pharmacovigilance Centre: the IC by the World Health Organization: and the EBGM by the FDA.…”